Biomarin Pharmaceutical Sees FY23 Adj. EPS $1.90-$2.05 vs $1.02 Est., Total Revenues $2.39B-$2.47B vs $2.45B Est.
Portfolio Pulse from Benzinga Newsdesk
Biomarin Pharmaceutical has projected its FY23 adjusted EPS to be between $1.90 and $2.05, which is significantly higher than the estimated $1.02. The company also expects total revenues to range from $2.39B to $2.47B, slightly below the estimated $2.45B.
November 01, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biomarin Pharmaceutical's FY23 adjusted EPS forecast is significantly higher than the estimate, which could positively impact the stock. However, the total revenue forecast is slightly below the estimate, which could have a negative effect.
The significantly higher EPS forecast for FY23 indicates strong profitability, which is a positive signal for investors and could drive the stock price up. However, the slightly lower revenue forecast could indicate potential challenges in sales or market growth, which could negatively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100